AgomAb Therapeutics NV (AGMB) Balance Sheet: Assets & Liabilities

AgomAb Therapeutics NV (AGMB) Balance Sheet

As of Mar 31, 2026 (end of fiscal 2025), AgomAb Therapeutics NV reported total assets of EUR 153.71M and total liabilities of EUR 22.80M. Shareholders' equity was EUR 130.90M, down 30.4% from EUR 188.08M a year earlier. Total debt stood at EUR 1.25M against EUR 116.51M in cash and short-term investments, a net cash position of EUR 115.26M. That puts debt-to-equity at 0.01, compared with 0.01 a year earlier.

AgomAb Therapeutics NV Balance Sheet Analysis

Values in millions EUR

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Balance sheet showing assets, liabilities, and shareholders' equity for AgomAb Therapeutics NV (AGMB) - Annual data in millions EUR
Breakdown	FY 2025	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2019	FY 2018
Period ending	Mar 2026	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2019	Dec 2018
Current Assets
Cash and Cash Equivalents	86.42	86.42	171.46	122.40	27.67	53.59	7.33	0.32
Short-Term Investments	30.10	30.10	-	-	40.00	-	-	-
Cash & Short-Term Investments	116.51	116.51	171.46	122.40	67.67	53.59	7.33	0.32
Accounts Receivable	4.78	4.09	2.12	16.95	3.33	0.83	0.16	0.01
Inventory	0.00	-	-	-	-	-	-	-
Other Current Assets	-0.06	4.72	2.39	0.00	-	-	-	-
Total Current Assets	121.24	121.24	173.85	139.47	71.09	54.43	7.48	0.33
Non-Current Assets
Property, Plant & Equipment (Net)	1.59	1.59	1.99	1.61	0.06	-	-	-
Long-Term Investments	0.01	0.01	0.01	-	-	-	-	-
Goodwill	10.11	8.61	8.61	8.61	8.61	8.61	-	-
Intangible Assets	23.62	20.11	20.11	20.11	20.11	20.11	-	-
Other Non-Current Assets	-2.86	2.15	1.79	1.46	1.13	-	-	-
Total Non-Current Assets	32.47	32.47	32.51	31.79	29.91	29.57	-	-
Total Assets	153.71	153.71	206.36	171.26	101.00	84.00	7.48	0.33
Current Liabilities
Accounts Payable	7.63	7.63	8.05	6.83	3.90	1.06	-	-
Short-Term Debt	0.25	-	-	-	-	-	-	-
Accrued Liabilities	-	2.46	0.80	1.47	0.70	0.36	-	-
Deferred Revenue	1.46	1.46	0.80	1.18	1.78	0.33	-	-
Other Current Liabilities	8.99	6.53	-	1.23	23.32	31.74	-	-
Total Current Liabilities	18.59	18.59	9.13	10.89	29.72	33.71	-	0.20
Non-Current Liabilities
Long-Term Debt	1.01	1.01	1.27	1.44	0.04	0.69	-	-
Deferred Tax Liabilities	0.00	-	-	-	0.62	3.29	-	-
Other Non-Current Liabilities	3.21	3.21	7.88	7.50	4.37	3.95	0.86	-
Total Non-Current Liabilities	4.22	4.22	9.15	8.94	5.03	7.93	-	-
Total Liabilities	22.80	22.80	18.28	19.82	34.75	41.64	0.86	0.20
Stockholders' Equity
Common Stock	223.07	223.07	223.07	0.03	0.03	84.40	10.18	0.64
Retained Earnings	-181.71	-181.71	-119.18	-72.83	-61.44	-44.82	-3.56	-0.51
Accumulated Other Comprehensive Income	-0.97	-0.97	-0.97	6.62	4.91	-0.30	-	-
Additional Paid-in Capital	90.51	76.63	76.63	42.94	12.37	-	-	-
Shares Outstanding	-	48.74	48.74	48.74	48.74	-	-	-
Total Stockholders' Equity	130.90	130.90	188.08	151.44	66.25	42.36	6.62	0.13
Total Liabilities & Equity	153.71	153.71	206.36	171.26	101.00	84.00	-	-

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About AgomAb Therapeutics NV Balance Sheet

How much debt does AgomAb Therapeutics NV have?

AgomAb Therapeutics NV had total debt of EUR 1.25M as of Mar 31, 2026, against EUR 116.51M in cash and short-term investments. Its debt-to-equity ratio was 0.01. Total debt was EUR 1.27M a year earlier.

What are AgomAb Therapeutics NV's total assets?

AgomAb Therapeutics NV reported total assets of EUR 153.71M as of Mar 31, 2026, down 25.5% from EUR 206.36M a year earlier. Total liabilities were EUR 22.80M.

What is AgomAb Therapeutics NV's shareholders' equity?

AgomAb Therapeutics NV's shareholders' equity was EUR 130.90M as of Mar 31, 2026.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition